Literature

Home
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Archie Prestayko, PhD
- Amanda Johnston, PhD
- W. Jenny Kung, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Steve Wu
- Advisory Board
- Lloyd J. Old, MD
- George Demetri, MD
- Robert C. Jackson, PhD
- Hsing-Jien Kung, MD PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
Pipeline
Collaborations
Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- Uricase-PEG 20:
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
- Histidase cancer treatment:
Company News
Contact

Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase

J.S. Bomalaski and M.A. Clark
Current Rheumatology Reports (2004), Vol. 6 pages 240-247

Uricase formulated with polyethylene glycol (uricase-PEG 20): Biochemical rationale and preclinical studies

J.S. Bomalaski, F.W. Holtsberg, C.M. Ensor and M.A Clark
Journal of Rheumatology (2002), Vol. 29 pages 1942-1949